COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

260 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-04-15

Study Completion Date

2021-01-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vitamin D is a secosteroid hormone produced by the skin during Summer exposure to UVB rays. Hypovitaminosis D is common in Winter (October to March) at Northern latitudes above 20 degrees North, and from April to September at Southern latitudes beyond 20 degrees below the equator.

In the past, coronaviruses and influenza viruses have exhibited very high seasonality, with outbreaks occurring preferentially during the Winter. The Covid-19 pandemic is indeed more severe above Winter latitudes of 20 degrees, while it remains until now less severe in the Southern hemisphere, with a much lower number of deaths.

Preclinical research suggests that the SARS-Cov-2 virus enters cells via the angiotensin converting enzyme 2 (ACE2). Coronavirus viral replication downregulates ACE2, thereby dysregulating the renin-angiotensin system (RAS) and leading to a cytokine storm in the host, causing acute respiratory distress syndrome (ARDS).

Research also shows that vitamin D plays a role in balancing RAS and in reducing lung damage. On the contrary, chronic hypovitaminosis D induces pulmonary fibrosis through activation of RAS. Similarly, hypovitaminosis D has been strongly associated in the literature with ARDS, as well as with a pejorative vital prognosis in resuscitation but also in geriatric units, and with various comorbidities associated to deaths during SARS-Cov-2 infections. Conversely, vitamin D supplementation has been reported to increase immunity and to reduce inflammatory responses and the risk of acute respiratory tract infections.

High-dose oral vitamin D3 supplementation has been shown to decrease short-term mortality in resuscitation patients with severe hypovitaminosis D (17% absolute risk reduction). It is considered safe to take oral vitamin D supplementation at doses up to 10,000 IU/day for short periods, particularly in older adults, i.e. a population that is mostly affected by hypovitaminosis D and who should receive at least 1,500 IU of vitamin D daily to ensure satisfactory vitamin D status.

Vitamin D supplementation is mentioned as a potentially interesting treatment for SARS-Cov-2 infection but on a scientific basis with a low level of evidence until now.

We hypothesize that high-dose vitamin D supplementation improves the prognosis of older patients diagnosed with COVID-19 compared to a standard dose of vitamin D.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cholecalciferol to Improve the Outcomes of COVID-19 Patients

NCT04411446

COVID

COMPLETED PHASE4

Vitamin D Testing and Treatment for COVID 19

NCT04407286

Covid 19 Vitamin D Deficiency

COMPLETED PHASE1

Vitamin D on Prevention and Treatment of COVID-19

NCT04334005

Patients Infected With COVID-19

UNKNOWN NA

Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease

NCT04952857

Covid19

COMPLETED PHASE4

Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients

NCT04386044

COVID-19 Vitamin D Deficiency

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

• Inclusion visit A clinical examination is carried out. Social-demographic measures, health history, clinical examination measures (including OSCI score) and biological measures are collected.

Randomization is conducted on the day of the inclusion visit. The ZYMAD® 400,000 IU (2 vials of 200,000 IU) or 50,000 IU (1 vial of 50,000 IU) treatment is given to the patient.

* Visit at day 7 A blood test is carried out by a nurse to determine the serum 25-OHD, creatrinine, albumine and calcium concentrations.
* Visit at day 14 A visit or telephone call allows recording the onset of clinical events of interest. The drugs received as part of the usual treatment during the last 14 days are collected.
* Visit at day 28 A visit or telephone call allows recording the onset of clinical events of interest. The drugs received as part of the usual treatment during the last 14 days are collected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronavirus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention group

High dose of vitamin D3

Group Type EXPERIMENTAL

cholecalciferol 200,000 IU

Intervention Type DRUG

Patients receive a vitamin D supplementation of 400,000 IU in a single oral dose.

Comparator group

Standard dose of vitamin D3

Group Type ACTIVE_COMPARATOR

cholecalciferol 50,000 IU

Intervention Type DRUG

Patients receive a vitamin D supplementation of 50,000 IU in a single oral dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cholecalciferol 200,000 IU

Patients receive a vitamin D supplementation of 400,000 IU in a single oral dose.

Intervention Type DRUG

cholecalciferol 50,000 IU

Patients receive a vitamin D supplementation of 50,000 IU in a single oral dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 65 years old
* Infection with COVID-19 diagnosed with RT-PCR SARS-CoV-2 or withCT-scan of the chest suggesting viral pneumonia of peripheral predominance in a clinically relevant context
* Patient seen in hospitalization or consultation or in nursing home
* Diagnosed within the preceding 3 days
* Having at least one of the following two risk factors for complications:

* age ≥75 years
* Peripheral capillary oxygen saturation (SpO2) ≤ 94% ambient air, or a partial oxygen pressure (PaO2) to fraction of inspired oxygen (FiO2) ratio ≤ 300 mmHg
* Patients affiliated with or benefitting from a social security scheme
* Written and signed consent of the patient or a relative or legal representative or, if not possible, emergency inclusion procedure

Exclusion Criteria

* Organ failure requiring admission to a resuscitation or high dependency unit
* Comorbidity that is life-threatening in the short-term (life expectancy \<3 months)
* Any reason that makes follow-up at day 28 impossible
* Vitamin D supplementation in the previous month, with the exception of treatment providing less than 800 IU of vitamin D per day
* Contraindication for vitamin D supplementation: active granulomatosis (sarcoidosis, tuberculosis, lymphoma), history of calcic lithiasis, known hypervitaminosis D or hypercalcemia, known intolerance to vitamin D
* Participation in another simultaneous trial
* Safeguard of justice
* Peripheral capillary oxygen saturation (SpO2) ≤92% in spite of an oxygen therapy \> 5L/min

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No